Sagimet issues updated January 2025 investor slide deck on MASH, acne, and cancer pipeline

Sagimet Biosciences Inc.

Updated slide presentation dated January 2025 addresses metabolic dysfunction therapies for MASH, acne, and oncology.
Presentation will be used in investor meetings; no financial results or clinical milestones disclosed in the filing.
No specific data, guidance, or material events announced; update appears to be routine corporate presentation refresh.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.